Non-metastatic muscle-invasive bladder cancer: the role of age in receiving treatment with curative intent

被引:5
|
作者
van Hoogstraten, Lisa M. C. [1 ,2 ]
Witjes, J. Alfred [3 ]
Meijer, Richard P. [4 ]
Ripping, Theodora M. [1 ]
Kiemeney, Lambertus A. [2 ,3 ]
Aben, Katja K. H. [1 ,2 ]
机构
[1] Netherlands Comprehens Canc Org, POB 1281, NL-6501 BG Utrecht, Netherlands
[2] Radboud Univ Nijmegen Med Ctr, Radboud Inst Hlth Sci, Nijmegen, Netherlands
[3] Radboud Univ Nijmegen Med Ctr, Dept Urol, Nijmegen, Netherlands
[4] Univ Med Ctr Utrecht, Dept Oncol Urol, Utrecht, Netherlands
关键词
muscle-invasive bladder cancer (MIBC); patient and tumour characteristics; survival; treatment; urothelial bladder carcinoma; variation in healthcare; #BladderCancer; #blcsm; LONG-TERM OUTCOMES; RADICAL CYSTECTOMY; MODALITY THERAPY; PRESERVATION; CHEMOTHERAPY; PATTERNS; SCORE;
D O I
10.1111/bju.15697
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives To evaluate which patient and tumour characteristics are associated with remaining untreated in patients with potentially curable, non-metastatic muscle-invasive bladder cancer (MIBC), and to compare survival of untreated vs treated patients with similar characteristics. Patients and methods For this cohort study, 15 047 patients diagnosed with cT2-T4aN0/xM0/x urothelial MIBC between 2005 and 2019 were identified in the Netherlands Cancer Registry. Factors associated with remaining untreated were identified using logistic regression analyses. Interhospital variation was assessed using multilevel analysis. Using a propensity score, the median overall survival (mOS) of untreated and treated patients was evaluated. Analyses were stratified by age (<75 vs >= 75 years). Results One-third of patients aged >= 75 years remained untreated; increasing age, worse performance status, worse renal function, cT4a stage and previous radiotherapy in the abdomen/pelvic area increased the odds of remaining untreated. One in 10 patients aged <75 years remained untreated; significant associations were only found for performance status, renal function and cT4a stage. Interhospital variation for remaining untreated was largest for patients aged >= 75 years, ranging from 37% to 69% (case-mix-adjusted). Irrespective of age, mOS was significantly worse for untreated patients: 6.4 months (95% confidence interval [CI] 5.1-7.3) vs 16.0 months (95% CI 13.5-19.1) for treated patients. Conclusion On average, one in five patients with non-metastatic MIBC remained untreated. Untreated patients were generally older and had a more unfavourable prognostic profile. Untreated patients had significantly worse overall survival, regardless of age. Age alone should therefore not affect treatment decision-making. Considering the large interhospital variation, a proportion of untreated patients might be wrongfully denied life-prolonging treatment.
引用
收藏
页码:764 / 775
页数:12
相关论文
共 50 条
  • [1] Usefulness of neoadjuvant chemotherapy in non-metastatic muscle-invasive bladder cancer
    Esper Rueda, J. A.
    Carrion Lopez, P.
    Donate Moreno, M. J.
    Herais Raya, L.
    Sanchez Migallon, I. Diaz de Mera
    Legido Gomez, O.
    Rico Marco, S.
    Martinez Ruiz, J.
    Nogueron Martinez, E.
    Salinas Sanchez, A. S.
    ACTAS UROLOGICAS ESPANOLAS, 2021, 45 (04): : 300 - 308
  • [2] Perioperative chemotherapy and immunotherapy to optimize cystectomy outcomes in the curative intent of non-metastatic muscle-invasive bladder cancer: A systematic review and meta-analysis
    Boutaleb, Ismail
    Mjaess, Georges
    Roumeguere, Thierry
    FRENCH JOURNAL OF UROLOGY, 2024, 34 (09):
  • [3] Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
    Chang, Sam S.
    Bochner, Bernard H.
    Chou, Roger
    Dreicer, Robert
    Kamat, Ashish M.
    Lerner, Seth P.
    Lotan, Yair
    Meeks, Joshua J.
    Michalski, Jeff M.
    Morgan, Todd M.
    Quale, Diane Z.
    Rosenberg, Jonathan E.
    Zietman, Anthony L.
    Holzbeierlein, Jeffrey M.
    JOURNAL OF UROLOGY, 2017, 198 (03) : 552 - 559
  • [4] Selective bladder preservation with curative intent for muscle-invasive bladder cancer: A contemporary review
    Koga, Fumitaka
    Kihara, Kazunori
    INTERNATIONAL JOURNAL OF UROLOGY, 2012, 19 (05) : 388 - 401
  • [5] Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024)
    Holzbeierlein, Jeffrey
    Bixler, Brooke R.
    Buckley, David I.
    Chang, Sam S.
    Holmes, Rebecca S.
    James, Andrew C.
    Kirkby, Erin
    McKiernan, James M.
    Schuckman, Anne
    JOURNAL OF UROLOGY, 2024, 212 (01) : 3 - 10
  • [6] The treatment of muscle-invasive bladder cancer in geriatric patients
    Grubmueller, Bernhard
    Seitz, Christian
    Shariat, Shahrokh F.
    CURRENT OPINION IN UROLOGY, 2016, 26 (02) : 160 - 164
  • [7] Beyond surgery: bladder preservation and the role of systemic treatment in localised muscle-invasive bladder cancer
    Swinton, Martin
    Devi, Aarani
    Song, Yee Pei
    Hoskin, Peter
    Choudhury, Ananya
    WORLD JOURNAL OF UROLOGY, 2024, 42 (01)
  • [8] Updates for the radiologist in non-muscle-invasive, muscle-invasive, and metastatic bladder cancer
    Choe, Jooae
    Braschi-Amirfarzan, Marta
    Tirumani, Sree Harsha
    Shinagare, Atul B.
    Kim, Kyung Won
    Ramaiya, Nikhil H.
    Krajewski, Katherine M.
    ABDOMINAL RADIOLOGY, 2017, 42 (11) : 2710 - 2724
  • [9] Is there a role for bladder preserving strategies in the treatment of muscle-invasive bladder cancer?
    Kuczyk, M
    Turkeri, L
    Hammerer, P
    Ravery, V
    EUROPEAN UROLOGY, 2003, 44 (01) : 57 - 64
  • [10] Chemotherapy for Muscle-Invasive Bladder Cancer
    Trenta, Patrizia
    Calabro, Fabio
    Cerbone, Linda
    Sternberg, Cora N.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (01) : 1 - 14